Ten South Asia Markets Compared: Key Medical Device Registration Metrics

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Placing the ten markets that GRZAN has already delivered side by side, the differences concentrate in five dimensions: the competent authority, the pathway structure, the validity period of the certificate, whether a local representative is mandatory, and the labelling language. Among these, the item most easily overlooked is that validity and fee models are not uniform — some markets renew every 5 years, some use long-term validity with annual or retention fees, and one applies a floating model priced in US dollars and converted monthly. Misjudging this leads directly to a lapsed certificate or a mis-budgeted programme.

The comparison below is built from delivery experience, which means every row has been used in a live project rather than compiled from desk research alone. That matters because registry websites describe rules, but not the operational weight of each rule — which is exactly what a portfolio decision needs.

2. Legal basis

The table consolidates the competent authority, pathway or certificate, validity, local representative requirement and labelling language for each market, with the governing instrument named where it exists.

MarketAuthorityPathway / certificateValidityLocal representativeLabelling language
MalaysiaMDA (Act 737)Registration after evaluation by a CAB (MDR 2012, P.U.(A) 500/2012)5 yearsForeign manufacturers must have an AREnglish / Malay
IndonesiaKemenkes (Ditjen Farmalkes)AKL / AKD (NIE), IDAK + CDAKB5 yearsMust be the local licence holder + importerIndonesian mandatory
VietnamMOH / IMDAsố lãu hành (MAC), Circular 05/2022/TT-BYTNo fixed validityLocal representative requiredVietnamese
ThailandThai FDA / MDCDClass 1 Listed; Class 2/3 Notified; Class 4 LicensedLicence 5 yearsLicence holder = importer = AR, one Thai entityThai
SingaporeHSAClass A exempt from registration; B/C/D registration (Immediate / Expedited / Abridged / Full)No fixed validity, maintained by annual feeForeign manufacturers must have a local representativeEnglish
PhilippinesFDA / CDRRHRClass A CMDN; B/C/D CMDR (AO 2018-0002)5 yearsLocal licence holder requiredEnglish
IndiaCDSCO (CLA / SLA)Import licence (MDR 2017, G.S.R. 78(E))Long-term validity + 5-year retention feeAR requiredEnglish
BangladeshDGDATwo steps: formulation approval + final registration (Class A is listing / DoC)Class A no time limit; B/C/D 5 yearsLAR requiredEnglish / Bengali
PakistanDRAP / MDMC (MDB)Class A Enlistment; B/C/D Registration5 yearsThe licensed importer is the AR (Rule 14(1)(b))English, with key safety information and basic instructions for household devices in Urdu
Sri LankaNMRA (Ministry of Health)Consolidated dossier: FMSA + PRD / PRD only; a reliance pathway also exists5 yearsMAH mandatory (local entity)Trilingual: English, Sinhala and Tamil (trilingual PIL mandatory for household devices)

3. Expert insights

Insight one: there are three validity models. Renewal every 5 years (Malaysia, Indonesia, Thailand, the Philippines, Bangladesh B/C/D, Pakistan and Sri Lanka), no fixed validity with fee-based maintenance (the MAC in Vietnam, annual fees in Singapore, the retention fee in India), and no time limit for Class A (Bangladesh). Treating 5 years as the default value produces errors in Vietnam, Singapore and India. The error surfaces late — typically when finance books a renewal provision that will never be spent, or when a certificate quietly lapses because no one was watching a fee deadline that replaces the renewal deadline. Validity model should therefore be recorded explicitly in the certificate ledger for every market in a portfolio, and the ledger entry should state what action keeps the certificate alive, not merely an expiry date.

Insight two: fee pricing also follows three models. Fixed in local currency (most markets), US-dollar conversion floating monthly (Sri Lanka), and no fixed fee but maintained annually or by five-year retention (Singapore and India). Sri Lanka is the only one of the ten markets where fees float monthly, so quotations must carry the month they were prepared in. A quote given in January cannot be honoured in June without restatement, and budget holders in other time zones often miss this until an invoice arrives changed. For Sri Lanka specifically, every internal approval and client proposal should carry the fee table of the submission month attached, so that the number quoted and the number paid remain the same number.

Insight three: classification nomenclature runs on two systems. Apart from Sri Lanka, the other nine markets use a single A–D (or equivalent) letter system; Sri Lanka is the only market with a dual track of Roman numerals for general devices plus letters for IVDs, and the only one that adds a separate listed-device category. The consequence runs through the whole project: pathway, dossier composition, timeline and fees all branch on the classification decision. A product misread under the wrong nomenclature is not slightly delayed — it is routed to a process that does not apply to it at all.

4. Practical recommendations

What GRZAN uses on multi-country parallel programmes is one comparison table plus ten certificate ledgers: the comparison table serves strategic decisions — which market to enter first and how to sequence resources — while the ledger serves execution management — when each certificate falls due, who renews it, and what fee event keeps it alive. Only the two instruments together keep a multi-country registration programme under control. The comparison table is stable and changes only when a regulation changes; the ledger moves constantly, as certificates are granted, renewed and maintained. Keeping them separate also keeps the audiences separate: leadership reads the table, operations owns the ledger, and neither document is asked to do the other’s job.

5. Verification checklist

  • □ The competent authority and pathway name of the target market have been confirmed
  • □ The validity model of that market’s certificate has been confirmed (5-year renewal / long-term with fees / no time limit)
  • □ The fee pricing model of that market has been confirmed (local currency / US-dollar conversion / retention fee)
  • □ Whether a local representative is mandatory, and its legal title, have been confirmed
  • □ Labelling language requirements have been confirmed (whether the local language is mandatory)
  • □ Renewal ledgers have been established separately under each market’s rules

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail